Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Spiculated cells (echinocytes and acanthocytes) and target cells

INTRODUCTION

A variety of morphologic alterations in red blood cells (RBCs) can be induced by changes in the cell membrane. Three of the most common variants, namely spiculated cells (echinocytes and acanthocytes) and target cells, will be discussed here. Other variants such as stomatocytes (hydrocytes) (picture 1) and xerocytes (dessicocytes) (picture 2) are discussed separately. (See "Stomatocytosis" and "Xerocytosis".)

ECHINOCYTES AND ACANTHOCYTES

Definitions — Echinocytes and acanthocytes are two types of spiculated red blood cells. A freshly prepared peripheral blood smear is essential for distinguishing between these cell types [1]; wet preparations or scanning electron microscopy may also be useful.

Echinocytes (also called burr cells) have serrated edges over the entire surface of the cell and often appear crenated in a blood smear (picture 3). Although often confused with acanthocytes, the projections of the red cell membrane are smaller and much more uniform in shape and distribution in echinocytes.

Acanthocytes (from the Greek acantha "thorn") have only a few spicules of varying size that project from the cell surface at irregular intervals (picture 4). They appear contracted and dense on stained peripheral blood smears. Spur cells appear to be the extreme form of acanthocytes and are seen in patients with severe liver disease (see 'Liver disease' below). Spur cells are felt to be acanthocytes remodeled by the spleen, whereby the spicules become more blunt and the associated membrane loss makes the cell more spherocytic (spheroacanthocyte).

Pathophysiology — The shape of these cells is thought to be related to changes in the organization of cell membrane components. In acanthocytes, this is often due to a defect in the lipid or protein composition of red cell membrane. In a study of patients with chorea-acanthocytosis and McLeod syndrome, for example, acanthocytes had a greater tendency to form spikes than normal RBCs in an incubation system, indicating their weakness against membrane tension [2]. Focal changes in the membrane skeleton appeared to predispose to the acanthocyte phenotype. In one patient echinocytes were present in association with a massive splenic hemangioma and disappeared following splenectomy [3].

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Mar 24, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Anoop P, Parker-Williams J. Morphological diagnosis of abetalipoproteinemia and the importance of a freshly prepared peripheral smear. Eur J Haematol 2009; 83:606.
  2. Terada N, Fujii Y, Ueda H, et al. Ultrastructural changes of erythrocyte membrane skeletons in chorea-acanthocytosis and McLeod syndrome revealed by the quick-freezing and deep-etching method. Acta Haematol 1999; 101:25.
  3. Altomare I, Desman G, Aledort LM. Echinocytosis--an unusual manifestation of hemangioma. Am J Hematol 2006; 81:532.
  4. Wong P. A basis of the acanthocytosis in inherited and acquired disorders. Med Hypotheses 2004; 62:966.
  5. Hasler CR, Owen GR, Brunner W, Reinhart WH. Echinocytosis induced by haemodialysis. Nephrol Dial Transplant 1998; 13:3132.
  6. Owen JS, Brown DJ, Harry DS, et al. Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins. J Clin Invest 1985; 76:2275.
  7. Cooper RA. Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 1980; 17:103.
  8. SMITH JA, LONERGAN ET, STERLING K. SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS. N Engl J Med 1964; 271:396.
  9. Grahn EP, Dietz AA, Stefani SS, Donnelly WJ. Burr cells, hemolytic anemia and cirrhosis. Am J Med 1968; 45:78.
  10. Salvioli G, Rioli G, Lugli R, Salati R. Membrane lipid composition of red blood cells in liver disease: regression of spur cell anaemia after infusion of polyunsaturated phosphatidylcholine. Gut 1978; 19:844.
  11. Shohet SE. Editorial: "Acanthocytogenesis"--or how the red cell won its spurs. N Engl J Med 1974; 290:1316.
  12. Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease. N Engl J Med 1974; 290:1279.
  13. Olivieri O, Guarini P, Negri M, et al. Increased proteolytic activity of erythrocyte membrane in spur cell anaemia. Br J Haematol 1988; 70:483.
  14. Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia. Blood 1996; 87:3489.
  15. Vassiliadis T, Mpoumponaris A, Vakalopoulou S, et al. Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. Hepatol Res 2010; 40:161.
  16. Allen DW, Manning N. Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes. Blood 1994; 84:1283.
  17. Chitale AA, Sterling RK, Post AB, et al. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 1998; 65:993.
  18. Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol 2005; 18:386.
  19. Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92.
  20. Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci 2005; 229-230:171.
  21. Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients. J Neurol 2005; 252:84.
  22. Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J 1983; 76:1008.
  23. Mant MJ, Faragher BS. The haematology of anorexia nervosa. Br J Haematol 1972; 23:737.
  24. Cynamon HA, Isenberg JN, Gustavson LP, Gourley WK. Erythrocyte lipid alterations in pediatric cholestatic liver disease: spur cell anemia of infancy. J Pediatr Gastroenterol Nutr 1985; 4:542.
  25. Sokol RJ, Guggenheim MA, Iannaccone ST, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580.
  26. Muller DP, Lloyd JK, Bird AC. Long-term management of abetalipoproteinaemia. Possible role for vitamin E. Arch Dis Child 1977; 52:209.
  27. Lesesve JF, Perrin J, Georges A, Morali A. Acanthocytosis in Anderson's disease. Br J Haematol 2009; 145:1.
  28. Udden MM, Umeda M, Hirano Y, Marcus DM. New abnormalities in the morphology, cell surface receptors, and electrolyte metabolism of In(Lu) erythrocytes. Blood 1987; 69:52.
  29. Telen MJ, Eisenbarth GS, Haynes BF. Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J Clin Invest 1983; 71:1878.
  30. Telen MJ. Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. Transfus Clin Biol 1995; 2:291.
  31. Telen MJ. The Lutheran antigens and proteins affected by Lutheran regulatory genes. In: Protein Blood Group Antigens of the Human Red Cell: Structure, Function and Clinical Significance, Agre PC, Cartron JP (Eds), Johns Hopkins University Press, Baltimore 1992. p.70.
  32. Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med 1976; 45:101.
  33. Wardrop C, Hutchison HE. Red-cell shape in hypothyroidism. Lancet 1969; 1:1243.
  34. Perillie PE, Tembrevilla C. Letter: Red-cell changes in hypothyroidism. Lancet 1975; 2:1151.
  35. AHERNE WA. The burr red cell and azotaemia. J Clin Pathol 1957; 10:252.
  36. LOGE JP, LANGE RD, MOORE CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958; 24:4.
  37. Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.
  38. Doll DC, List AF, Dayhoff DA, et al. Acanthocytosis associated with myelodysplasia. J Clin Oncol 1989; 7:1569.
  39. Fawaz NA, Beshlawi IO, Al Zadjali S, et al. dRTA and hemolytic anemia: first detailed description of SLC4A1 A858D mutation in homozygous state. Eur J Haematol 2012; 88:350.
  40. Müller U, Röthlin M. [Splenic neoformation following trauma-induced splenectomy--diagnosis and function]. Swiss Surg 1995; :230.
  41. Beutler E, West C, Tavassoli M, Grahn E. The Woronets trait: a new familial erythrocyte anomaly. Blood Cells 1980; 6:281.
  42. Filippini A, Villa G, Corrocher R, De Franceschi L. Acute hemolytic anemia with acanthocytosis associated with high-dose misoprostol for medical abortion. Ann Emerg Med 2007; 50:289.
  43. Gallagher PG, Forget BG, Lux SE. Disorders of the erythrocyte membrane. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), Saunders, Philadelphia 1997. p.544.
  44. Cooper RA, Jandl JH. Bile salts and cholesterol in the pathogenesis of target cells in obstructive jaundice. J Clin Invest 1968; 47:809.
  45. Cooper RA, Diloy Puray M, Lando P, Greenverg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest 1972; 51:3182.
  46. Neerhout RC. Abnormalities of erythrocyte stromal lipids in hepatic disease. J Lab Clin Med 1968; 71:438.
  47. Cooper RA, Jandl JH. The role of membrane lipids in the survival of red cells in hereditary spherocytosis. J Clin Invest 1969; 48:736.
  48. Funke H, von Eckardstein A, Pritchard PH, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991; 88:4855.
  49. Funke H, von Eckardstein A, Pritchard PH, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest 1993; 91:677.
  50. Gjone E, Torsvik H, Norum KR. Familial plasma cholesterol ester deficiency. A study of the erythrocytes. Scand J Clin Lab Invest 1968; 21:327.
  51. Norum KR, Gjone E. The influence of plasma from patients with familial plasma lecithin: cholesterol acyltransferase deficiency on the lipid pattern of erythrocytes. Scand J Clin Lab Invest 1968; 22:94.
  52. Frohlich J, Godolphin WJ, Reeve CE, Evelyn KA. Familial LCAT deficiency. Report of two patients from a Canadian family of Italian and Swedish descent. Scand J Clin Lab Invest Suppl 1978; 150:156.
  53. de Haan LD, Werre JM, Ruben AM, et al. Alterations in size, shape and osmotic behaviour of red cells after splenectomy: a study of their age dependence. Br J Haematol 1988; 69:71.
  54. Singer K, Weisz L. The life cycle of the erythrocyte after splenectomy and the problems of splenic hemolysis and target cell formation. Am J Med Sci 1945; 210:301.
  55. Singer K, Miller EB, et al. Hematologic changes following splenectomy in man, with particular reference to target cells, hemolytic index, and lysolecithin. Am J Med Sci 1941; 202:171.